Best Investments for 2015
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
Here are four stocks to watch with exceptional relative strength and technical momentum.
Blackstone's $8 billion deal for the life-science-focused real estate company, BioMed, is the latest in a string of REIT acquisitions.
Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.
Alder Biopharmaceuticals shares were hot this summer, but then fell by 32% in the past three months.
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $189.9 million dollar outflow -- that's a 8.7% decrease week over week (from 33,850,000 to 30,900,000). Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc is down about 1.9%, Spark Therapeutics Inc is up about 1.1%, and Sarepta Therapeutics Inc is lower by about 1.6%.
The Shanghai Composite reopened Thursday after a holiday and traded higher. How will the rest of the world markets trade?
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
Cramer finds Yum! completely unappetizing but sees good things ahead for Novocure.
China's stock market has been closed for a holiday and U.S. stocks have started to respond, Cramer says. But what happens if China has a bad day Thursday?
The following Monsanto (MON) conference call took place on October 7, 2015, 09:30 AM ET. This is a transcript of that earnings call:
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
The technicals are good, and traders can look at the stock again from the long side.
Cramer likes Cisco Systems' low valuation and exposure to the cyber security industry. He loves Celgene for its above-average growth and reasonable valuation.